Cannabidiol as a phytopharmaceutical for chronic pain: Integrative review
DOI:
https://doi.org/10.33448/rsd-v13i1.44866Keywords:
Phytodrugs; Cannabis sativa; Chronic pain treatment; Review.Abstract
The aim was to analyze the use of cannabidiol as a medicinal treatment for chronic pain by means of an integrative review. This is an Integrative Literature Review (ILR), which set out to identify, synthesize and carry out an extended analysis of the herbal use of cannabidiol. Thirty pieces of literature were selected for full reading and presentation of the results, as they met the objectives. The samples came from 85% of the Medline/PubMed database, in the last five years, with 60% of them using a cross-sectional approach and descriptive nature, and 84% of the patients studied in the studies reported an improvement in the level of chronic and/or neuropathic pain after starting to use Cannabis. In addition to this benefit, others mentioned in the articles were improved sleep and its quality, as well as reduced opioid consumption. With regard to the origin of the pain, half said it was linked to one or more causes, and chronic pain including cancer (nonspecific, intractable and other) was the most mentioned (80%). There is important consensus that medical cannabis can be approved for populations with inflammatory, nociplastic, neuropathic and mixed pain, however, if you are considering using CBD to treat chronic pain or any other MMJ-based condition, it is essential to discuss this with a doctor or healthcare professional to ensure that it is safe and appropriate for your specific situation. In this sense, more studies should be carried out to prove the importance and effectiveness of cannabidiol in the treatment of chronic pain, both from a clinical, review and statistical point of view.
References
Ajrawat, P., Yang, Y., Wasilewski, E., et al. (2022). Medical cannabis use and inflammatory cytokines and chemokines among adult chronic pain patients. Cannabis Cannabinoid Res. 4(11):1-21.
Ascenção, M. D, Lustosa, V. R., & Silva, L. J. (2016). Canabinoides no tratamento da dor crônica. Revista de Medicina e Saúde de Brasília. 5(3): 255-63.
Barros, A., & Peres, M. (2012). Proibição da maconha no Brasil e suas raízes históricas escravocratas. Revista Periferia. 3(2):1-12.
Baron, E. P., Lucas, P., Eades, J., & Hogue, O. (2018). Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 19(1):37-51.
Banerjee, S., & McCormack, S. (2019). CADTH rapid response reports, in Medical cannabis for the treatment of chronic pain: A review of clinical effectiveness and guidelines (Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 13(2):10-22.
Bhaskar, A., Bell, A., Boivin, M., et al. (2021). Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: Results of a modified Delphi process. J. Cannabis Res. 3 (1):22.
Britch, S. C. (2017). Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity. Drug Alcohol Depend. 175(3):187-197.
Bobitt, J., Kang, H., Croker, J. A., et al. (2020). Use of cannabis and opioids for chronic pain by older adults: Distinguishing clinical and contextual influences. Drug Alcohol Rev. 39 (6): 753-762.
Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J. Pain. 17(2), 739-744.
Boehnke, K. F., Scott, J. R., Litinas, E., et al. (2019). Pills to pot: Observational analyses of cannabis substitution among medical cannabis users with chronic pain. J. Pain. 20(7):830-841.
Busse, J. W., Vankrunkelsven, P., Zeng, L., et al. (2021). Medical cannabis or cannabinoids for chronic pain: A clinical practice guideline. Bmj. 374(8), 1-15.
Caetano, R. M. (2019). Influência de aspectos políticos e culturais no desenvolvimento de pesquisas que empregam o uso de canabinoides. Monografia (Graduação em Farmácia). Universidade Federal de Ouro Preto, Ouro Preto, 47p.
Cardoso, G. K. S., Lopes, W. L., & Primini, E. O. (2023). Cannabidiol modulates chronic neuropathic pain aversion behavior by attenuation of neuroinflammation markers and neuronal activity in the corticolimbic circuit in male Wistar rats. Behav Brain Res. 24(452), 114588.
Gunter, A., & Kubrusly, R. C. (2018). Efeito do Sistema endocanabinoide no desenvolvimento de culturas de células de retina de galinha após exposição aguda e crônica ao Win 55, 212-2. Monografia (Graduação em Biomedicina) – Instituto Biomédico. Universidade Federal Fluminense, Niterói, 54.
Hegazy, O., & Platnick, H. (2019). Cannabidiol (CBD) for Treatment of Neurofibromatosis-related Pain and Concomitant Mood Disorder: A Case Report. Cureus, 11(12), e6312.
Kovic, S. V., Srebro, D., Vujovic, K. S. et al. (2018). Cannabinoids and Pain: New Insights From Old Molecules. Front. Pharmacol. 9(2), 1259.
Hill, K. P. (2015). Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. Jama. 313(24), 2474-83.
Machado, L. S. R., Assis, N. M. L., & Rodrigues, J. L. G. (2022). Potencial analgésico do canabidiol no tratamento da dor crônica: uma revisão integrativa. Artigos.Com 34(1), e10352.
Maher, D. P., Carr, D. B., Hill, K., et al. (2019). Cannabis for the Treatment of Chronic Pain in the Era of an Opioid Epidemic: A Symposium-Based Review of Sociomedical Science. Pain Med. 20(11):2311-2323.
Matias, G. F. S., Lima, M. A. C., Costa, T. A., et al. (2022). Research, Society and Development. 11(3), 1-12.
Mattos, P. C. (2015). Tipos de revisão de literatura. Unesp, 1-9. Recuperado de https://www.fca.unesp.br/Home/Biblioteca/tipos-de-evisao-de-literatura.pdf
Meng, H., Page, M. G., Ajrawat, P., et al. (2021). Patient-reported outcomes in those consuming medical cannabis: A prospective longitudinal observational study in chronic pain patients. Can. J. Anaesth. 68(5), 633-644.
Pernoncini, K. V., & Oliveira, R. M. M. W. (2018). Usos terapêuticos potenciais do canabidiol obtido da Cannabis sativa. Revista UningáReview, 20(3), 1-18.
Piper, B. J., Beals, M. L., Abess, A. T., et al. (2017). Chronic pain patients' perspectives of medical cannabis. Pain. 158(7), 1373-1379.
Sampaio, M. F., et al. (2021). O potencial terapêutico neurológico dos componentes da Cannabis sativa. Brazilian Journal of Surgery and Clinical Research, 34(1), 52-60.
Sandoval, A. R., Kolano, A. L., & Vázquez, P. A. A. (2017). Cannabis and Cannabinoids for Chronic Pain. Curr Rheumatol Rep. 19(11), 67-79.
Sandoval, A. R., Fincham, J. E., Kolano, A. L., Sharpe, B. N., & Vázquez, P. A. A. (2018). Cannabis for Chronic Pain: Challenges and Considerations. Pharmacotherapy. 38(6), 651-662.]
Sihota, A., Smith, B. K., Ahmed, S. A., et al. (2021). Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int. J. Clin. Pract. 75(8), e13871.
Simões, M. C., Teixeira, L. da C., Cardoso, M. B. S., et al. (2021). O conhecimento tradicional para construção de uma horta medicinal em Salvaterra, Ilha de Marajó, Pará. HOLOS, 4(2), 1-12.
Urits, I., Gress, K., Charipova, K., et al. (2020). Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol. 34(3), 463-477.
Wessler, B. G. (2014). Efeitos neuroquímicos e comportamentais causados pelo uso da Cannabis Sativa. Monografia apresentada ao Setor de Pós-graduação da Universidade do Extremo Sul Catarinense-UNESC, para a obtenção do título de especialista em Farmacologia.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ademara Guimarães; Camila Araujo; Francisco Soares Neto; Marcella Pimenta Pereira Cruz; Thames Dantas da Silva; Isabela Guerreiro Diniz; Márcia Cristina Monteiro Guimarães
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
